Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Recursion Pharmaceuticals ( (RXRX) ).
In a strategic move, the Company finalized its acquisition of Exscientia, making it a wholly-owned subsidiary. The transaction involved exchanging Exscientia shares for the Company’s Class A Common Stock, leading to Exscientia’s delisting from Nasdaq. Notable executive changes followed, with Franziska Michor joining the Company’s board, Ben Taylor becoming CFO, and Christopher Gibson assuming the role of President alongside his CEO duties. Additionally, operational changes and a new equity incentive plan were announced, signaling a fresh phase of growth and innovation.
Learn more about RXRX stock on TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
